THE BEST OF TCOYD
Two Paths, One Choice: What Happens When You Take Control of Your Type 2 Diabetes
Type 2 diabetes rarely travels alone. It often shows up alongside heart, kidney, and liver conditions–the cluster known as metabolic syndrome–and in the early stages, there are no symptoms. Without symptoms pushing you to act, it’s easy to put things off, skip doses, or leave appointments feeling like there’s no rush. But the damage keeps moving in the background, and preventing complications early is far more effective than trying to slow them down later. The good news is the opposite is also true: the earlier you engage, the more you can protect. Staying curious about your health, understanding what today’s treatments like GLP-1s can do, and advocating for care that fits your life is what turns a diagnosis into a plan. And if you’re not where you want to be right now, today is just a starting point!
Mastering Difficult Meals with Modern Automated Insulin Delivery (AID) Technology
There are currently five automated insulin delivery (AID) systems available for people with diabetes, and in this episode, we are putting two powerhouses head-to-head: the MiniMed™ (Medtronic) 780G and the twiist™. By testing these systems against a notoriously difficult California Burrito, we demonstrate how adaptive algorithms and customizable settings—like the twiist™ pre-meal target range and the MiniMed™ 780G’s auto-corrections every 5 minutes—can empower you to navigate even the most challenging menus with confidence.
Mounjaro for Type 1s, Time-Restricted Eating Results, Finerenone for Kidney Disease in Type 1 & A "Huge" Ozempic Story | TCOYD® Newsy News #6
In this video, you will learn about the following:
Eli Lilly’s new “Surpass T1D” study investigating the use of Mounjaro (tirzepatide) for weight loss and blood sugar control in Type 1 diabetes
Impressive data on Time-Restricted Eating showing how a 4-hour feeding window improved pancreatic function and insulin resistance in early Type 2 diabetes
Results from the “Fine-One” Phase 3 trial demonstrating that Finerenone can prevent the progression of chronic kidney disease in adults with Type 1 diabetes
A factual (and humorous) report on how significant weight loss from GLP-1s like Ozempic can visually increase penile length
An impromptu “Joke Off” between Drs. Edelman and Pettus to celebrate the lighter side of medical news
Leave a Reply